Merus (NASDAQ:MRUS – Get Free Report) had its price objective boosted by equities research analysts at Guggenheim from $93.00 to $111.00 in a report released on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. Guggenheim’s price target suggests a potential upside of 119.54% from the company’s current price.
A number of other equities analysts have also commented on the stock. Citigroup lifted their price target on shares of Merus from $70.00 to $93.00 and gave the company a “buy” rating in a research report on Wednesday, June 26th. Stifel Nicolaus boosted their target price on shares of Merus from $90.00 to $99.00 and gave the stock a “buy” rating in a research report on Monday, June 17th. Canaccord Genuity Group restated a “buy” rating and set a $67.00 price target on shares of Merus in a report on Thursday, July 25th. Needham & Company LLC dropped their price objective on Merus from $92.00 to $85.00 and set a “buy” rating on the stock in a research note on Monday, August 5th. Finally, Bank of America restated a “buy” rating and set a $76.00 target price on shares of Merus in a research note on Tuesday, June 25th. One analyst has rated the stock with a sell rating, ten have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, Merus presently has a consensus rating of “Buy” and an average target price of $82.00.
Check Out Our Latest Report on Merus
Merus Price Performance
Merus (NASDAQ:MRUS – Get Free Report) last issued its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($0.81) EPS for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.05). Merus had a negative net margin of 476.41% and a negative return on equity of 36.33%. The company had revenue of $7.33 million for the quarter, compared to analyst estimates of $9.64 million. As a group, sell-side analysts anticipate that Merus will post -3.27 earnings per share for the current year.
Institutional Trading of Merus
A number of hedge funds have recently modified their holdings of the company. Price T Rowe Associates Inc. MD bought a new stake in shares of Merus during the first quarter valued at approximately $53,377,000. Marshall Wace LLP boosted its stake in Merus by 813.3% during the second quarter. Marshall Wace LLP now owns 957,952 shares of the biotechnology company’s stock worth $56,682,000 after buying an additional 853,060 shares in the last quarter. Logos Global Management LP bought a new stake in Merus in the 2nd quarter valued at $50,294,000. Novo Holdings A S bought a new stake in Merus in the 2nd quarter valued at $39,940,000. Finally, Avoro Capital Advisors LLC raised its stake in shares of Merus by 52.4% in the 2nd quarter. Avoro Capital Advisors LLC now owns 1,355,000 shares of the biotechnology company’s stock valued at $80,175,000 after buying an additional 466,112 shares in the last quarter. Institutional investors own 96.14% of the company’s stock.
Merus Company Profile
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.
Recommended Stories
- Five stocks we like better than Merus
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- S&P 500 Hitting Resistance: These 3 Stocks Offer the Best Upside
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Nike’s Post-Earnings Drop Presents a Buying Opportunity
- Differences Between Momentum Investing and Long Term Investing
- Microsoft’s Targeted Upside Might Be Too Good to Ignore
Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.